1Q 2026 FDA New Drug Approvals

Prodigy continues to closely monitor new to market drugs approved by the U.S. Food and Drug Administration (FDA). This Q1 2026 pipeline report captures all novel drug approvals, regardless of whether they are currently indicated for conditions traditionally associated with workers’ compensation claims. By providing early insight into emerging and first in class therapies, many of which target rare, pediatric, or highly specialized conditions, this report equips claims professionals with timely background information that may prove valuable if these medications enter treatment plans through indicated or off label use. Staying informed about evolving therapeutic options supports more informed decision making and proactive claims management.